Prostatype Genomics Financials
| PROGEN Stock | SEK 1.00 0.02 2.04% |
Prostatype |
Please note, the presentation of Prostatype Genomics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Prostatype Genomics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Prostatype Genomics' management manipulating its earnings.
Prostatype Genomics Stock Summary
Prostatype Genomics competes with Devyser Diagnostics, IZafe Group, Sprint Bioscience, and Stayble Therapeutics. Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. The company was founded in 2007 and is based in Solna, Sweden. Prostatype Genomics is traded on Stockholm Stock Exchange in Sweden.| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0014684569 |
| Business Address | Industrivgen 19, Solna, |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Benchmark | Dow Jones Industrial |
| Website | www.prostatypegenomics.com |
| Phone | 46 08 20 87 00 |
| Currency | SEK - Swedish Kronor |
You should never invest in Prostatype Genomics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Prostatype Stock, because this is throwing your money away. Analyzing the key information contained in Prostatype Genomics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Prostatype Genomics Key Financial Ratios
Prostatype Genomics' financial ratios allow both analysts and investors to convert raw data from Prostatype Genomics' financial statements into concise, actionable information that can be used to evaluate the performance of Prostatype Genomics over time and compare it to other companies across industries.| Return On Equity | -0.7 | |||
| Return On Asset | -0.39 | |||
| Target Price | 21.02 | |||
| Beta | 1.22 | |||
| Z Score | 28.8 |
Prostatype Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Prostatype Genomics's current stock value. Our valuation model uses many indicators to compare Prostatype Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Prostatype Genomics competition to find correlations between indicators driving Prostatype Genomics's intrinsic value. More Info.Prostatype Genomics AB is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Prostatype Genomics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Prostatype Genomics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Prostatype Genomics Systematic Risk
Prostatype Genomics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Prostatype Genomics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Prostatype Genomics correlated with the market. If Beta is less than 0 Prostatype Genomics generally moves in the opposite direction as compared to the market. If Prostatype Genomics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Prostatype Genomics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Prostatype Genomics is generally in the same direction as the market. If Beta > 1 Prostatype Genomics moves generally in the same direction as, but more than the movement of the benchmark.
Prostatype Genomics July 19, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Prostatype Genomics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Prostatype Genomics AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of Prostatype Genomics AB based on widely used predictive technical indicators. In general, we focus on analyzing Prostatype Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Prostatype Genomics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 77.78 | |||
| Value At Risk | (30.54) | |||
| Potential Upside | 25.0 |
Complementary Tools for Prostatype Stock analysis
When running Prostatype Genomics' price analysis, check to measure Prostatype Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prostatype Genomics is operating at the current time. Most of Prostatype Genomics' value examination focuses on studying past and present price action to predict the probability of Prostatype Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prostatype Genomics' price. Additionally, you may evaluate how the addition of Prostatype Genomics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |